Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9
2
Introduction 10
2.1 What Is This Report About? 10
3 Definitions of the
Markets Covered in the Report 11
3.1 Diabetes Care Devices 11
3.2
Glucose Monitoring 11
3.2.1 Blood Glucose Meter 11
3.2.2 Blood Glucose
Strips 11
3.3 Insulin Delivery 11
3.3.1 Insulin Pen 11
3.3.2
Insulin Pump 11
3.3.3 Insulin Syringes 11
4 Healthcare Sector Review
13
4.1 Healthcare Expenditure 13
4.2 Healthcare Infrastructure 16
4.3 Healthcare Policy 20
5 Regulation System 21
5.1 Medical Equipment
Approval Process 21
5.1.1 Classification 21
5.1.2 Premarket
Notification for Class I Devices 22
5.1.3 Pre-market Approval for Class
II, III and IV Devices 22
5.1.4 License Fee 23
5.1.5 License
Application Processing Duration 23
5.2 Post-market Surveillance 24
6
Pricing and Reimbursement 25
7 Distribution Structure 28
7.1
Distribution Structure 28
8 Diabetes Care Devices In Republic of Korea
29
8.1 Diabetes Care Devices Cross Country Comparison (2000-2012) 29
8.2 Diabetes Care Devices, Republic of Korea, Overall Revenues ($ mn),
2000-2012 30
8.3 Diabetes Care Devices, Republic of Korea, Category Volume
(Units), 2000-2012 34
8.4 Diabetes Care Devices, Republic of Korea,
Company Share (2006-2007) 37
9 Glucose Monitoring In Republic of Korea
38
9.1 Glucose Monitoring Overall Revenue (2000-2012) 38
9.2 Glucose
Monitoring Overall Volume (2000-2012) 40
9.3 Glucose Monitoring Average
Price (2000-2012) 42
9.4 Glucose Monitoring Distribution Share (2006-2007)
43
9.5 Glucose Monitoring, Republic of Korea, Company Share (2006-2007)
44
10 Insulin Delivery In Republic of Korea 45
10.1 Insulin Delivery
Overall Revenue (2000-2012) 45
10.2 Insulin Delivery Overall Volume
(2000-2012) 47
10.3 Insulin Delivery Average Price (2000-2012) 48
10.4
Insulin Delivery Distribution Share (2006-2007) 49
10.5 Insulin Delivery,
Republic of Korea, Company Share (2006-2007) 50
11 F. Hoffmann-La Roche
Ltd. Company Profile 51
11.1 Company Overview 51
11.2 Value Chain
Analysis 51
11.2.1 Manufacturing 52
11.2.2 Product Development 52
11.2.3 Sales and Marketing 53
12 LifeScan, Inc. Company Profile 55
12.1 Company Overview 55
12.1.1 LifeScan, Inc. Pipeline Products by
Equipment Type 56
12.1.2 LifeScan, Inc. Pipeline Products by Development
Stage 56
12.1.3 LifeScan, Inc. Pipeline Products by Therapy Area 56
12.1.4 LifeScan, Inc. Pipeline Products by Clinical Trials 56
12.1.5
LifeScan, Inc. Pipeline Products by News Summary 56
13 Abbott Laboratories
Company Profile 57
13.1 Company Overview 57
13.2 Value Chain Analysis
57
13.2.1 Manufacturing 58
13.2.2 Product Development 58
13.2.3
Sales and Marketing 59
13.2.4 Abbott Laboratories Pipeline Products by
Equipment Type 59
13.2.5 Abbott Laboratories Pipeline Products by
Development Stage 60
13.2.6 Abbott Laboratories Pipeline Products by
Therapy Area 60
13.2.7 Abbott Laboratories Pipeline Products by Clinical
Trials 60
13.2.8 Abbott Laboratories Pipeline Products by News Summary
60
14 Bayer HealthCare AG Company Profile 61
14.1 Company Overview
61
14.2 Value Chain Analysis 61
14.2.1 Manufacturing 62
14.2.2
Product Development 62
14.2.3 Sales and Marketing 63
14.3 Bayer
HealthCare AG Pipeline Products 63
14.3.1 Bayer HealthCare AG Pipeline
Products by Equipment Type 63
14.3.2 Bayer HealthCare AG Pipeline Products
by Development Stage 64
14.3.3 Bayer HealthCare AG Pipeline Products by
Therapy Area 64
14.3.4 Bayer HealthCare AG Pipeline Products by News
Summary 64
15 Novo Nordisk A/S Company Profile 65
15.1 Company
Overview 65
15.1.1 Novo Nordisk A/S Pipeline Products by Equipment Type
66
15.1.2 Novo Nordisk A/S Pipeline Products by Development Stage 66
15.1.3 Novo Nordisk A/S Pipeline Products by Therapy Area 66
15.1.4 Novo
Nordisk A/S Pipeline Products by Clinical Trials 66
16 Eli Lilly and
Company Company Profile 67
16.1 Company Overview 67
16.2 Value Chain
Analysis 67
16.2.1 Manufacturing 68
16.2.2 Product Development 68
16.2.3 Sales and Marketing 69
16.2.4 Eli Lilly and Company Pipeline
Products by Equipment Type 70
16.2.5 Eli Lilly and Company Pipeline
Products by Development Stage 70
16.2.6 Eli Lilly and Company Pipeline
Products by Therapy Area 70
17 Abbott Korea Limited Company Profile 71
17.1 Company Overview 71
18 Shin Chang Medical Co., Ltd. Company Profile
72
18.1 Company Overview 72
19 Shina Corporation Company Profile
73
19.1 Company Overview 73
20 Appendix 74
20.1 Global Markets
Direct Research Methodology 74
20.2 Coverage 75
20.3 Secondary
Research 75
20.4 Primary Research 76
20.5 Models 76
20.6 Forecasts
77
20.7 Expert Panels 77
20.8 Currency Conversion 78
20.9 Contact
Us 79
20.10 Disclaimer 79
1.1 List of Tables
Table 1:
Hospital Wards by Specialty in Republic of Korea, 2003-2007 17
Table 2:
Doctors by Specialty in Republic of Korea, 2003-2007 18
Table 3:
Healthcare Institutions in Republic of Korea, 2001-2005 19
Table 4:
Healthcare Personnel in Republic of Korea, 1975-2002 19
Table 5:
Classification of Medical Equipment in Republic of Korea 21
Table 6:
Diabetes Care Devices Cross Country Comparison (2000-2012) 29
Table 7:
Diabetes Care Devices, Republic of Korea, Overall Revenues ($ mn), 2000-2012
30
Table 8: Diabetes Care Devices, Republic of Korea, Portfolio Analysis,
2000-2012 31
Table 9: Diabetes Care Devices, Republic of Korea,
Overall Revenues ($ mn), Historic, 2000-2007 32
Table 10: Diabetes
Care Devices, Republic of Korea, Overall Revenues ($ mn), Forecast, 2007-2012
33
Table 11: Diabetes Care Devices, Republic of Korea, Category
Volume (Units), 2000-2012 34
Table 12: Diabetes Care Devices,
Republic of Korea, Category Volume (Units), Historic, 2000-2007 35
Table
13: Diabetes Care Devices, Republic of Korea, Category Volume (Units),
Forecast, 2007-2012 36
Table 14: Diabetes Care Devices, Republic of
Korea, Company Share by Revenue ($ mn), 2006-2007 37
Table 15:
Glucose Monitoring, Republic of Korea, Revenue ($ mn) by Segment, Historic,
2000-2007 38
Table 16: Glucose Monitoring, Republic of Korea, Revenue
($ mn) by Segment, Forecast, 2007-2012 39
Table 17: Glucose
Monitoring, Republic of Korea, Overall Volume (Units), Historic, 2000-2007
40
Table 18: Glucose Monitoring, Republic of Korea, Overall Volume
(Units), Forecast, 2007-2012 41
Table 19: Glucose Monitoring,
Republic of Korea, Average Price ($), Historic, 2000-2007 42
Table 20:
Glucose Monitoring, Republic of Korea, Average Price ($), Forecast, 2007-2012
42
Table 21: Glucose Monitoring, Republic of Korea, Distribution
Share by Revenue ($mn), 2006-2007 43
Table 22: Glucose Monitoring,
Republic of Korea, Company Share by Revenue ($ mn), 2006-2007 44
Table 23:
Insulin Delivery, Republic of Korea, Revenue ($ mn) by Segment, Historic,
2000-2007 45
Table 24: Insulin Delivery, Republic of Korea, Revenue
($ mn) by Segment, Forecast, 2007-2012 46
Table 25: Insulin Delivery,
Republic of Korea, Overall Volume (Units), Historic, 2000-2007 47
Table
26: Insulin Delivery, Republic of Korea, Overall Volume (Units),
Forecast, 2007-2012 47
Table 27: Insulin Delivery, Republic of Korea,
Average Price ($), Historic, 2000-2007 48
Table 28: Insulin Delivery,
Republic of Korea, Average Price ($), Forecast, 2007-2012 48
Table 29:
Insulin Delivery, Republic of Korea, Distribution Share by Revenue ($mn),
2006-2007 49
Table 30: Insulin Delivery, Republic of Korea, Company
Share by Revenue ($ mn), 2006-2007 50
Table 31: LifeScan, Inc.
Pipeline Products by Equipment Type 56
Table 32: LifeScan, Inc.
Pipeline Products by Development Stage 56
Table 33: LifeScan, Inc.
Pipeline Products By Therapy Area 56
Table 34: LifeScan, Inc.
Pipeline Products By Clinical Trials 56
Table 35: LifeScan, Inc.
Pipeline Products By News Summaries 56
Table 36: Abbott Laboratories
Pipeline Products by Equipment Type 59
Table 37: Abbott Laboratories
Pipeline Products By Development Stage 60
Table 38: Abbott
Laboratories Pipeline Products By Therapy Area 60
Table 39: Abbott
Laboratories Pipeline Products By Clinical Trials 60
Table 40: Abbott
Laboratories Pipeline Products By News Summaries 60
Table 41: Bayer
HealthCare AG Pipeline Products by Equipment Type 63
Table 42: Bayer
HealthCare AG Pipeline Products By Development Stage 64
Table 43:
Bayer HealthCare AG Pipeline Products By Therapy Area 64
Table 44:
Bayer HealthCare AG Pipeline Products By News Summaries 64
Table 45:
Novo Nordisk A/S Pipeline Products by Equipment Type 66
Table 46:
Novo Nordisk A/S Pipeline Products By Development Stage 66
Table 47:
Novo Nordisk A/S Pipeline Products By Therapy Area 66
Table 48: Novo
Nordisk A/S Pipeline Products By Clinical Trials 66
Table 49: Eli
Lilly and Company Pipeline Products by Equipment Type 70
Table 50:
Eli Lilly and Company Pipeline Products by Development Stage 70
Table 51:
Eli Lilly and Company Pipeline Products By Therapy Area 70
Table 52:
Currency Conversion from USD to Local Currency at 2007 Constant Rate 78
1.2 List of Figures
Figure 1: Healthcare Financing in Republic of
Korea, 2007 14
Figure 2: Healthcare Expenditure in Republic of Korea, 2000
- 2006 15
Figure 3: Evaluation (Value Appraisal) Criteria for Medical
Device Reimbursement in Republic of Korea, 2007 26
Figure 4: Medical
Device Pricing System in Republic of Korea, 2007 27
Figure 5:
Diabetes Care Devices Cross Country Comparison (2000-2012) 29
Figure 6:
Diabetes Care Devices, Republic of Korea, Overall Revenues ($ mn), 2000-2012
30
Figure 7: Diabetes Care Devices, Republic of Korea, Portfolio Analysis,
2000-2012 31
Figure 8: Diabetes Care Devices, Republic of Korea,
Overall Revenues ($ mn), Historic, 2000-2007 32
Figure 9: Diabetes
Care Devices, Republic of Korea, Overall Revenues ($ mn), Forecast, 2007-2012
33
Figure 10: Diabetes Care Devices, Republic of Korea, Category
Volume (Units), 2000-2012 34
Figure 11: Diabetes Care Devices,
Republic of Korea, Category Volume (Units), Historic, 2000-2007 35
Figure
12: Diabetes Care Devices, Republic of Korea, Category Volume (Units),
Forecast, 2007-2012 36
Figure 13: Diabetes Care Devices, Republic of
Korea, Company Share (%), 2007 37
Figure 14: Glucose Monitoring,
Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2007 38
Figure 15: Glucose Monitoring, Republic of Korea, Revenue ($ mn) by
Segment, Forecast, 2007-2012 39
Figure 16: Glucose Monitoring,
Republic of Korea, Overall Volume (Units), Historic, 2000-2007 40
Figure
17: Glucose Monitoring, Republic of Korea, Overall Volume (Units),
Forecast, 2007-2012 41
Figure 18: Glucose Monitoring, Republic of
Korea, Company Share (%), 2007 44
Figure 19: Insulin Delivery,
Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2007 45
Figure 20: Insulin Delivery, Republic of Korea, Revenue ($ mn) by
Segment, Forecast, 2007-2012 46
Figure 21: Insulin Delivery, Republic
of Korea, Company Share (%), 2007 50
Figure 22: F. Hoffmann-La Roche
Ltd Value Chain Analysis 51
Figure 23: Abbott Laboratories Value
Chain Analysis 57
Figure 24: Bayer HealthCare AG Value Chain Analysis
61
Figure 25: Eli Lilly and Company Value Chain Analysis 67
Figure 26: Global Markets Direct Methodology 74
|
Related Report
|
View Cart
